Physician profile
John Gaidry
NPI 1215967906
$378.24
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $84.61 · 2021: $33.84 · 2022: $74.30.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $197.35 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $56.45 | 2022 | |
| Avanir Pharmaceuticals, INC. | $32.26 | 2019-2021 | |
| Alkermes, INC. | $23.54 | 2019 | |
| Sun Pharmaceutical Industries INC. | $20.04 | 2021 | |
| Urovant Sciences INC | $17.85 | 2022 | |
| Lilly USA, LLC | $17.19 | 2020 | |
| Acadia Pharmaceuticals INC | $13.56 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gaidry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.